Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer

British Journal of Cancer

Volumn 79, Issue 5-6, 1999, Pages 909-914

  Pujol, P ^a,d   Daures J P ^b   Brouillet, J P ^a   Maudelonde, T ^a   Rochefort, H ^a   Grenier, J ^c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c Centre Régional de Lutte Contre le Cancer   (France)

^d HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Breast cancer; Cathepsin D; Menopause; Menstrual cycle; pS2

Indexed keywords

CATHEPSIN D; ESTRADIOL; ESTROGEN; FOLLITROPIN; LUTEINIZING HORMONE; PROGESTERONE; PROTEIN PS2; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER SURGERY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; FOLLITROPIN BLOOD LEVEL; HUMAN; LUTEAL PHASE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MENOPAUSE; MENSTRUAL CYCLE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROGNOSIS; PROTEIN EXPRESSION; RADIOIMMUNOASSAY;

BREAST NEOPLASMS; CATHEPSIN D; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; GROWTH SUBSTANCES; HUMANS; LUTEINIZING HORMONE; MENOPAUSE; MENSTRUAL CYCLE; PROGESTERONE; PROSPECTIVE STUDIES; PROTEINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEINS;

EID: 0033039221     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690145     Document Type: Article

References (35)

1. Badwe RA, Gregory WM, Chaudary MA, Richards MA, Bentley AE, Rubens RD and Fentiman IS (1991) Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet 337: 1261-1264
2. Badwe RA, Bettelheim R, Millis RR, Gregory W, Richards MA and Fentiman IS (1995) Cyclical tumour variations in premenopausal women with early breast cancer. Eur J Cancer 13: 2181-2184
3. Cazin JL, Gosselin P, Boniface B and Demaille A (1993) Expression of PS2 and cathepsin D in breast cancer. Int J Oncol 2: 1081-1084
4. Clark GM and McGuire WL (1988) Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15: 20-25
5. Coradini D, Cappelleti V, Miodini P, Ronchi E, Scavone G and Di Fronzo G (1984) Variations in estrogen and progesterone receptor content in premenopausal breast cancer patients throughout the menstrual cycle. Tumori 70: 339-344
6. Fentiman IS, Gregory WM and Richards MA (1994) Effect of menstrual phase on surgical treatment of breast cancer. Lancet 344: 402
7. Ferrandina G, Scambia G, Benedetti Panici P, Mancuso S and Messori A (1997) Relationship between cathepsin D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer 76: 661-666
8. Foekens JA, Rio MC, Seguin P, Van Putten WLJ, Fauque J, Nap M, Klijn JGM and Chambon P (1990) Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50: 3832-3837
9. Gion M, Mione R, Dittadi R, Romanelli M, Capitanio G, Friede U, Barbazza R, Visona A and Dante S (1995) Relationship between cathepsin D and other pathological and biological parameters in 1752 patients with primary breast cancer. Eur J Cancer 31A: 671-677
10. Granata G, Coradini D, Cappeletti V and Difronzo G (1991) Prognostic relevance of cathepsin D vs oestrogen receptors in node-negative breast cancer. Eur J Cancer 27: 970-972
11. Henry JA, Nicholson S, Hannesy C, Lennard T, May F and Westley B (1989) Expression of the oestrogen related pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy. Br J Cancer 63: 32-38
12. Holdaway IM, Mason BH, Lethaby AE, Harman JE, France JT and Knox BS (1997) Characteristics of the menstrual cycle at the time of surgery for breast cancer. Br J Cancer 75: 413-416
13. Holli K, Isola J and Hakama M (1995) Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient - fact or fallacy. Br J Cancer 71: 124-127
14. Khan SA, Gonchoroff NJ and Miller LE (1997) Expression of pS2, c-erbB-2, and cathepsin D during the menstrual cycle in human breast cancers. Ann Surg Oncol 4: 462-469
15. Korenman SG (1969) Comparative binding of estrogens and its relation to estrogenic potency. Steroids 13: 163-178
16. Lowry OH, Roseborough N, Farr L and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275
17. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A and Chambon P (1982) Cloning of cDNA sequences of hormone-related genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10: 7895-7903
18. Maudelonde T, Escot C, Pujol P, Rouanet P, Defrenne A, Brouillet JP and Rochefort H (1994) In vivo stimulation by tamoxifen of cathepsin D mRNA level in breast cancer. Eur J Cancer 30A: 2049-2053
19. Mohr PE, Wang DY, Gregory WM, Richards MA and Fentiman IS (1996) Serum progesterone and prognosis in operable breast cancer. Br J Cancer 73: 1552-1555
20. Oliver DJ and Ingram DM (1995) Timing of surgery during the menstrual cycle for breast cancer: possible role of growth factors. Eur J Cancer 3: 325-328
21. Osborne CK, Yochmowitz MG, Knight WA and McGuire WL (1980) The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 36: 2884-2888
22. Pink JJ and Jordan VC (1996) Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56: 2321-2330
23. Powles TJ, Ashley SE, Nash AG, Tidy A, Gazet JC and Ford HT (1991) Menstrual surgical timing (letter). Lancet 337: 1604
24. Predine J, Spyratos F, Prud'homme JF, Andrieu C, Hacene K, Brunet M, Pallud C and Milgrom E (1992) Enzyme-linked immunosorbent assay of pS2 in breast cancers benign tumors, and normal breast tissues. Cancer 69: 2116-2123
25. Pujol P, Maudelonde T, Daures JP, Rouanet P, Brouillet JP, Pujol H and Rochefort H (1993) A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 71: 2006-2012
26. Pujol P, Daures JP, Thezenas S, Guilleux F, Rouanet P and Grenier J (1998) Changing estrogen and progesterone receptor patterns in breast cancer during the menstrual cycle und menopause. Cancer 83: 698-705
27. Rageth JC, Wyss P, Unger C and Hochuli E (1991) Timing of breast cancer surgery within the menstrual cycle: influence on lymph-node involvement, receptor status, postoperative metastatic spread and local recurrence. Ann Oncol 2: 269-272
28. Rochefort H (1992) Biological and clinical significance of cathepsin D in breast cancer. Acta Oncol 31: 125-130
29. Saad Z, Bramwell VHC, Wilson SM, O'Malley FP, Jeacock J and Chambers AF (1998) Expression of genes that contribute to proliferate and metastatic ability in breast cancer resected during various menstrual phases. Lancet 351: 1170-1173
30. Schwartz L, Koerner F, Edgerton SM, Sawicka JM, Rio MC, Bellocq JP, Chamhon P and Thor D (1991) pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 51: 624-628
31. Senie RT, Rosen PP, Rhodes P and Lesser ML (1991) Timing of breast cancer excision during the menstrual cycle influences the duration of disease-free survival. Ann Intern Med 115: 337-342
32. Spyratos F, Andrieu C, Hacene K, Chambon P and Rio MC (1994) pS2 and response to adjuvant hormone therapy in primary breast cancer. Br J Cancer 69: 394-397
33. Tandon AK, Clark GM, Chamness GC, Chirgwin JM and McGuire WL (1990) Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297-302
34. Veronesi U, Luini A, Mariani L, Del Vecchio M, Alvez D, Andreoli C, Giacobone A, Merson M, Pacetti G, Raselli R and Saccozzi R (1994) Effect of menstrual phase on surgical treatment of breast cancer. Lancet 343: 1544-1546
35. Westley BR and Rochefort H (1980) A secreted glycoprotein induced by estrogen in human breast cancer cell line. Cell 20: 352-362